Mohit Kaushal, MD


Mohit Kaushal is the newest member of the Aberdare team, joining as a partner in 2013.

Mohit has had an extensive career within clinical medicine, venture capital and health policy. He was most recently the inaugural Chief Strategy Officer and Executive Vice President of Business Development at West Health a unique set of entities focused on lowering health care costs through medical research, healthcare policy and investment. He developed the West Health Investment Fund strategy, sourced and led investments in Humedica (acquired by Optum Health), Change Healthcare, RxAnte and goBalto.

Previously, Mohit was the Director of Connected Health with the Federal Communications Commission, where he established the agency’s first dedicated health care team. During his time in the Obama administration, he was also a member of the White House Health IT task force, a cross agency team focusing on implementing the technology aspects of Health Reform. Prior to this position, Kaushal was an investment professional at Polaris Venture Partners, and worked for Merrill Lynch’s Health Care Investment Banking Group and the World Health Organization. Kaushal holds an MBA from Stanford and an MD with distinction from Imperial College, London.

In addition to his role at Aberdare Ventures, Mohit is an Adjunct Assistant Professor of Emergency Medicine at George Washington University and serves on the curation team at TEDMED. He has been appointed to the Consumer Technology Workgroup of the Health IT Standards Committee and to the National Committee on Vital and Health Statistics advising HHS on Data Access and Use.

Current investments
goBalto, RxAnte

Select past investments
Change Healthcare, Humedica

Joined Aberdare in 2013

Broad experience in clinical medicine, academic research, venture capital, and health policy

Stanford M.B.A.; Imperial College of Science, Technology and Medicine (London), M.D.

Jake Odden


Jake Odden joined Aberdare at its inception in 1999, and serves as Partner and Chief Operating Officer.

His responsibilities at Aberdare include overseeing the finance, operating and administrative functions of the firm. He is a primary interface with the firm’s limited partners and has led all of the fund formation efforts during his tenure at Aberdare. Additionally, Jake helps supervise the firm’s investment process as it relates to managing deal flow as well as all elements of consummating a new or follow-on investment opportunity. During his time with the firm he has also worked closely with many of Aberdare’s portfolio companies.

Jake’s entire career has been spent working in a variety of investment, advisory and finance positions. Prior to Aberdare, he worked at The Walt Disney Company where he was active in both e-commerce business development and strategic planning for the consumer products division. Earlier, after beginning his career at the Vanguard Group, Jake spent several years at Goldman Sachs where he was a member of the corporate finance group in New York, advising clients of varying sizes and industries on achieving their financial and strategic objectives.

Jake received his AB from Bowdoin College and his MBA from the Amos Tuck School at Dartmouth.

Joined Aberdare at inception in 1999

Leads finance, operations, administrative and investment process efforts

Tuck School at Dartmouth M.B.A.; Bowdoin College A.B.

Sigrid Van Bladel, PhD


Sigrid Van Bladel, Ph.D. joined Aberdare Ventures as a Venture Partner in 2011.

She previously was a Partner at New Enterprise Associates (NEA), a leading venture capital firm focusing on technology and healthcare start-ups, where she spent 18 years investing in biopharmaceutical and medical device companies.

During her investing career, Sigrid has a long, well established record of backing early-stage healthcare technology enterprises. Successful exits where she was an investor and Board member include Myogen (formerly NASDAQ: MYOG, acquired by Gilead); Kai Pharma (an Aberdare investment acquired by Amgen); Novacept (acquired by Cytyc/Hologic); SurgRx (acquired by Johnson and Johnson); Xcel Pharmaceuticals (acquired by Valeant Pharma); Appriva Medical (acquired by EV3/Covidien); and Spiration Inc. (acquired by Olympus Medical Systems).

For two years in a row during her tenure at NEA, Sigrid was included on Forbes Magazine’s Annual Midas List of the top 100 leading technology money makers, as only one of five women included on the list.

Prior to joining NEA, Sigrid worked as a Management Consultant at McKinsey and Company.  She received a “Licenciaat” in Chemistry/Biotechnology (summa cum laude) from the University of Ghent in Belgium, where her first place ranking in the nation earned her a four-year Ph.D. full scholarship from the National Science Foundation of Belgium. Sigrid earned a PhD (summa cum laude) in Molecular Biology from The University of Ghent, Belgium, and an MBA from the Stanford Graduate School of Business.

Current investments
Aviir, Conatus

Select past investments
Kai, Myogen, Novacept, SurgRx

Joined Aberdare in 2011

20 years experience in healthcare venture capital

Stanford MBA; “Licenciaat” in Chemistry/Biotechnology and PhD in Molecular Biology, University of Ghent, Belgium

Darren Hite


Darren Hite serves as Partner, having joined the firm in 2006.

Darren focuses on investments addressing key inefficiencies in large healthcare markets, and his efforts have helped catapult Aberdare into a leadership position at the intersection of healthcare and the new wave of information technology. More recently, Darren has led Aberdare’s investment efforts in healthcare technology companies outside of the US.

Darren manages Aberdare’s commitments in companies that bring transparency and efficiency to clinical trial management (goBalto), consumer wellness (Jiff), and medication adherence (RxAnte) and he is the Director of Special Projects at mc10. He was a founding investor in Rock Health, the premier incubator for healthcare technology companies based in San Francisco and is a mentor for early stage healthcare technology companies through his involvement with Rock Health, Blueprint Health, UCSF, and Stanford.

Prior to Aberdare, Darren has spent his career in clinical medicine, finance, and  entrepreneurship. He was a corporate strategy associate at Medtronic and an investment banking analyst and co-founder of the eHealth group at Robertson Stephens.

Darren attended the MD program at Georgetown University School of Medicine and the Biodesign program at Stanford University. He holds an AB in Evolutionary Biology from Princeton University and an MBA from the Stanford Graduate School of Business.

Current investments
goBalto, Jiff, mc10, RxAnte

Joined Aberdare in 2006

Driver of Aberdare’s efforts in Transformational Healthcare

Stanford M.B.A.; Stanford Biodesign; Georgetown University School of Medicine; Princeton A.B.

Paul Klingenstein


Paul Klingenstein founded Aberdare in 1999.

His recent focus has been on technologies which drive transformational efficiencies in care, leading Aberdare commitments in areas such as personalized medicine (Clovis Oncology) and biosensor systems and data analytics (mc10, RxAnte).  Earlier at Aberdare, he helped establish the firm as a leading healthcare venture investor through commitments to more traditional technologies such as drug discovery and development (Pharmion, Ironwood, Anacor) and highly engineered interventional devices (Nevro, Ablation Frontiers).

Prior to founding Aberdare, Paul was an advisor to the Rockefeller Foundation, where he helped launch an early public private partnership (IAVI), directed at finding a broadly effective vaccine for HIV.

At Accel Partners (1986 – 1997) he led a highly successful healthcare effort. He invested in and served on the board of Aviron, Isis Pharmaceuticals, Viagene, Neurex, Glycomed, US Behavioral Health, Amerigroup, Xomed Surgical Products, and others.

After working as a field biologist and Outward Bound instructor in Africa, he began his investment career at Warburg Pincus in New York. In the early 1980s, he had the opportunity to be a participant in an earlier wave of systemic transformation, through his involvement in first generation biotechnology (Synergen, Vestar) and managed care (U.S. Healthcare).

Paul serves on the board of the John D. and Catherine T. MacArthur Foundation, The London School of Hygiene and Tropical Medicine and the Campaign Legal Center.  He is a former Board Chair of the International AIDS Vaccine Initiative and of Juma Ventures, and a former Trustee of the Taft School and of the Marin Country Day School.

He is a rancher, fisherman, and backcountry pilot, and received his AB in anthropology from Harvard and his MBA from Stanford.


Current investments
Anacor, Aviir, Clovis Oncology, Conatus Pharmaceuticals, ElationEMR, mc10

Select past investments
Aviron, EP Technologies, Idun, Ironwood, Isis, Pharmion, Salmedix

Founded Aberdare in 1999

25 years at leading edge of healthcare venture capital

Stanford M.B.A.; Harvard A.B.